|
1
|
Macneill AJ, Miceli R, Strauss DC,
Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro
D, Hayes AJ, Honoré C, et al: Post-relapse outcomes after primary
extended resection of retroperitoneal sarcoma: A report from the
Trans-Atlantic RPS Working Group. Cancer. 123:1971–1978. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maurice MJ, Yih JM, Ammori JB and
Abouassaly R: Predictors of surgical quality for retroperitoneal
sarcoma: Volume matters. J Surg Oncol. 116:766–774. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mak KS, Phillips JG, Barysauskas CM, Lee
LK, Mannarino EG, Van Benthuysen L, Raut CP, Mullen JT, Fairweather
M, DeLaney TF and Baldini EH: Acute gastrointestinal toxicity and
bowel bag dose-volume parameters for preoperative radiation therapy
for retroperitoneal sarcoma. Pract Radiat Oncol. 6:360–366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee HS, Yu JI, Lim DH and Kim SJ:
Retroperitoneal liposarcoma: The role of adjuvant radiation therapy
and the prognostic factors. Radiat Oncol J. 34:216–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alqasem K, Abukhiran I, Jasser J, Bisharat
T, Ellati RT, Khzouz J, Al-Saidi I and Al-Daghamin A:
Clinico-pathological outcomes of post-primary and salvage
chemotherapy retroperitoneal lymph node dissection for mixed germ
cell tumors, King Hussein Cancer Center experience. Turk J Urol.
42:256–260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mano R, Becerra MF, Carver BS, Bosl GJ,
Motzer RJ, Bajorin DF, Feldman DR and Sheinfeld J: Clinical outcome
of patients with Fibrosis/Necrosis at post-chemotherapy
retroperitoneal lymph node dissection for advanced germ cell
tumors. J Urol. 197:391–397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stillström D, Nilsson H, Jesse M,
Peterhans M, Jonas E and Freedman J: A new technique for minimally
invasive irreversible electroporation of tumors in the head and
body of the pancreas. Surgical Endosc. 31:1982–1985. 2017.
View Article : Google Scholar
|
|
8
|
Langan RC, Goldman DA, D'Angelica MI,
Dematteo RP, Allen PJ, Balachandran VP, Jarnagin WR and Kingham TP:
Recurrence patterns following irreversible electroporation for
hepatic malignancies. J Surg Oncol. 115:704–710. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song ZQ, Xu XH, Pan ZH, Yao CG and Zhou
QH: Mechanisms for steep pulse irreversible electroporation
technology to kill human large cell lung cancer cells L9981. Int J
Clin Exp Med. 7:2386–2394. 2014.PubMed/NCBI
|
|
10
|
Martin RC, Schwartz E, Adams JA, Farah I
and Derhake BM: Intra-operative anesthesia management in patients
undergoing surgical irreversible electroporation of the pancreas,
Liver, Kidney, and retroperitoneal tumors. Anesth Pain Med.
5:e227862015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scheltema MJ, Postema AW, de Bruin DM,
Buijs M, Engelbrecht MR, Laguna MP, Wijkstra H, de Reijke TM and de
la Rosette JJMCH: Irreversible electroporation for the treatment of
localized prostate cancer: A summary of imaging findings and
treatment feedback. Diagn Interv Radiol. 23:365–370. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kos B, Voigt P, Miklavcic D and Moche M:
Careful treatment planning enables safe ablation of liver tumors
adjacent to major blood vessels by percutaneous irreversible
electroporation (IRE). Radiol Oncol. 49:234–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chai W, Tian G and Jiang T: Percutaneous
irreversible electroporation for portal vein tumor thrombus: A case
report. Ultrasound Q. 33:296–299. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bijur PE, Silver W and Gallagher EJ:
Reliability of the visual analog scale for measurement of acute
pain. Acad Emerg Med. 8:1153–1157. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giesinger JM, Kuijpers W, Young T,
Tomaszewski KA, Friend E, Zabernigg A, Holzner B and Aaronson NK:
Thresholds for clinical importance for four key domains of the
EORTC QLQ-C30: Physical functioning, emotional functioning, fatigue
and pain. Health Qual Life Outcomes. 14:872016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dunki-Jacobs EM, Philips P and Martin RC
II: Evaluation of thermal injury to liver, pancreas and kidney
during irreversible electroporation in an in vivo experimental
model. Br J Surg. 101:1113–1121. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Underhill CE, Walsh NJ, Bateson BP,
Mentzer C and Kruse EJ: Feasibility and safety of irreversible
electroporation in locally advanced pelvic and retroperitoneal
tumors. Am Surg. 82:e263–e265. 2016.PubMed/NCBI
|
|
18
|
Kambakamba P, Bonvini JM, Glenck M,
Castrezana López L, Pfammatter T, Clavien PA and DeOliveira ML:
Intraoperative adverse events during irreversible electroporation-a
call for caution. Am J Surg. 212:715–721. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qin Z, Zeng J, Liu G, Long X, Fang G, Li
Z, Xu K and Niu L: Irreversible electroporation ablation of an
unresectable fibrous sarcoma with 2 electrodes: A case report.
Technol Cancer Res Treat. Jan 1–2017.doi: 10.1177/1533034617711530
(Epub ahead of print). View Article : Google Scholar
|
|
20
|
Meng Z, Garrett CR, Shen Y, Liu L, Yang P,
Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ and Cohen L: Prospective
randomised evaluation of traditional Chinese medicine combined with
chemotherapy: A randomised phase II study of wild toad extract plus
gemcitabine in patients with advanced pancreatic adenocarcinomas.
Br J Cancer. 107:411–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martin RC II, Kwon D, Chalikonda S,
Sellers M, Kotz E, Scoggins CM, McMasters KM and Watkins K:
Treatment of 200 locally advanced (stage III) pancreatic
adenocarcinoma patients with irreversible electroporation: Safety
and efficacy. Ann Surg. 262:486–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Narayanan G, Hosein PJ, Beulaygue IC,
Froud T, Scheffer HJ, Venkat SR, Echenique AM, Hevert EC,
Livingstone AS, Rocha-Lima CM, et al: Percutaneous image-guided
irreversible electroporation for the treatment of unresectable,
locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol.
28:342–348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ansari D, Kristoffersson S, Andersson R
and Bergenfeldt M: The role of irreversible electroporation (IRE)
for locally advanced pancreatic cancer: A systematic review of
safety and efficacy. Scand J Gastroenterol. 52:1165–1171. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee EW, Thai S and Kee ST: Irreversible
electroporation: A novel image-guided cancer therapy. Gut Liver. 4
(Suppl 1):S99–S104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bulvik BE, Rozenblum N, Gourevich S, Ahmed
M, Andriyanov AV, Galun E and Goldberg SN: Irreversible
electroporation versus radiofrequency ablation: A comparison of
local and systemic effects in a Small-animal model. Radiology.
280:413–424. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Distelmaier M, Barabasch A, Heil P,
Kraemer NA, Isfort P, Keil S, Kuhl CK and Bruners P: Midterm safety
and efficacy of irreversible electroporation of malignant liver
tumors located close to major portal or hepatic veins. Radiology.
285:1023–1031. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schwarze JE, Jeria R, Crosby J, Villa S,
Ortega C and Pommer R: Is there a reason to perform ICSI in the
absence of male factor? Lessons from the latin american registry of
ART. Hum Reprod Open. 2017:hox0132017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Joong Choi C, Roh YH, Kim MC, Choi HJ, Kim
YH and Jung GJ: Single-port laparoscopic cholecystectomy for gall
bladder polyps. JSLS. 19(pii): e2014.00183. 2015.PubMed/NCBI
|
|
29
|
Pirracchio R, Sprung CL, Payen D and
Chevret S: Utility of time-dependent
inverse-probability-of-treatment weights to analyze observational
cohorts in the intensive care unit. J Clin Epidemiol. 64:1373–1382.
2011. View Article : Google Scholar : PubMed/NCBI
|
